Trial Profile

Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary) ; Cetuximab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms AFACET

Most Recent Events

31 Oct 2023 Primary endpoint has been met. (Disease control rate after 18 weeks)
31 Oct 2023 Results published in the Cancer
26 Jun 2023 This trial has been completed in Netherlands (End Date: 06 Sep 2022), according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com